Azathioprine and cyclophosphamide as slow-acting drugs for rheumatoid arthritis.
Therapy with azathioprine and cyclophosphamide is described as reducing disease activity in rheumatoid arthritis. The well recognized untoward effects are tractable save for the definite augmentation of carcinogenesis, a measurable risk that is regarded as acceptable in treating rheumatoid arthritis with azathioprine and rheumatoid arteritis with cyclophosphamide.
D001167:Arteritis / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced
D003520:Cyclophosphamide; D001379:Azathioprine